Russian investment fund, Gamaleya Center set up scientific board on Sputnik V

MOSCOW, January 18. /TASS/. The Russian Direct Investment Fund (RDIF) and the National Research Center for Epidemiology and Microbiology named after N.F. Gamaleya (Gamaleya Center) have set up an International Scientific Advisory Board on the Sputnik V vaccine, the Fund said in a statement on Monday. "RDIF and the Gamaleya Center initiated the creation of the International Scientific Advisory Board on the Sputnik V vaccine and the formation of an international platform where vaccine developers could exchange information, opinions and expertise with their leading foreign colleagues," Chief Executive Officer of the Russian Direct Investment Fund Kirill Dmitriev was quoted as saying. Particularly, apart from Director of the Gamaleya Center Alexander Gintsburg and Deputy Director for Science of the Gamaleya Center Denis Logunov, the list of participants of the board includes Adjunct Professor, Department of Microbiology, University of Buenos Aires, School of Medicine, Carlos Zala, President of the society of infectologists (Argentina) Omar Sued, Professor of Medical Microbiology at the University of East Anglia David Livermore, Professor of Gene Therapies, President of the British Society for Gene and Cell Therapy Len Seymour, Principal Investigator on Vaccine Development, the Institute for Virology of the University Hospital in Essen (Germany) Wibke Bayer, M.D. Microbiology, National Institute of Mental Health and Neurosciences (NIMHANS) (India) Vasanthapuram Ravi, Research Director, Institute of Molecular and Cellular Pharmacology (France) Cecil Czerkinsky, Professor, Vaccine & Immunotherapy Center (the US) Hildegund Ertl, Associate Professor of Microbiology & Immunology, Wake Forest School of Medicine Biotech Place (the US) David Ornelles, Professor, Faculty of Medicine, Lomonosov Moscow State University, Deputy Chief Physician for Anesthesiology and Reanimation at Hospital No. 52 in Moscow Sergey Tsarenko, and others. The Sputnik V vaccine is the world’s first registered vaccine against coronavirus. It is based on a proven and well-studied platform of human adenoviral vectors. Read more